DAFTAR PUSTAKA

Abdulkarim, B.S., Cuartero, J., Hanson, J., Deschênes, J., Lesniak, D., Sabri, S., 2011, Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol ;29:2852–8.

Akobeng, A.K. 2007. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Pædiatrica. 96; 644–647.

Ahmad, A.R., Tan, J.S., Manivannan, A.B., Wahid, M.I., 2019, Breast cancer survivorship in an Asian specialist centre from Malaysia: A retrospective analysis, Asian Journal of Medical Sciences | Nov-Dec 2019 | Vol 10 | Issue 6, Website:http://nepjol.info/index.php/AJMS, DOI: 10.3126/ajms.v10i6.25885.

American Cancer Society, 2019, Triple Negative Breast Cancer, cited 2020 May 10 available from: https://www.cancer.org/cancer/breast-cancer/ understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple

Bader, A.G., 2012, miR-34 - A microRNA replacement therapy is headed to the clinic. Front Genet. 3, doi:10.3389/fgene.2012.00120.

Bartel D.P., 2009, MicroRNAs: target recognition and regulatory functions. Cell; 136: 215-33.

Beg, S., Siraj, A.K., Prabhakaran ,S., Jehan, Z., Ajarim, D., Al-Dayel, F., Tulbah, A., Al-Kuraya, K.S., 2015, Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer. Breast Cancer Res Treat ; 151: 541-53.

Bertoli, G., Cava, C., Castiglioni, I., 2015, MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics ; 5: 1122-43.

Cao, Z.G., Li, J.J., Yao, L., Huang, Y.N., Liu, Y.R., Hu, X., *et al.,* 2016, High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer. Oncotarget;7:64900–9.

Cascione, L., Gasparini, P., 2013, Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 8, e55910.

Chen, J., Tian, W., 2012, Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med. Oncol. 29, 2527–2534.

Clark, T.G., Bradburn, M.J., Love, S.B., Altman, D.G. 2003. Survival Analysis Part I: Basic concepts and first analyses. Br J Cancer, 89(2): 232–238.

Cully, M., You, H., Levine, A.J., Mak, T.W., 2006, Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6:184–92.

Dent, R., Hanna, W.M., Trudeau, M., Rawlinson, E., Sun, P., Narod, S.A., 2009, Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115:423–8.

Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A., 2007, Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence, American Association for Cancer Research, doi:10.1158/1078-0432.CCR-06-3045

Despa, S., 2017. What is Survival Analysis? [Online]. cited 2017 December Friday. Available from: https://www.cscu.cornell.edu/news/statnews/stnews78.pdf.

Dominika, P., Marcin, B., Radzislaw, K., Rafal, S., Hanna, R., 2018, MicroRNAs in regulation of triple-negative breast cancer progression, Journal of Cancer Research and Clinical Oncology, 144:1401–1411.

Dvinge H., Git A., 2013, Shaping and functional consequences of the microRNA landscape in breast cancer. Nature, 497, 378–382.

Elvira, D'Ippolito and Marilena, V. Iorio., 2013, MicroRNAs and Triple Negative Breast Cancer. Int. J. Mol. Sci.14, 22202-22220; doi:10.3390/ijms141122202.

GLOBOCAN 2018 : Estimated Cancer Incidence, Mortality and Prevalence Worldwide, 2018. www.globocan.iarc.fr

Gonçalves, H., Guerra, M.G., Duarte, J.R., Fayer, V.A., Vilela I., Bustamante M.T, 2018, Survival Study of Triple-Negative and Non–TripleNegative Breast Cancer in a Brazilian Cohort, Clinical Medicine Insights: Oncology Volume 12:1–10,sagepub.co.uk/journalsPermissions.nav, DOI:10.1177/1179554918790563

Graveel, C.R., Calderone, H.M., Westerhuis, J.J., Winn, M.E., Sempere, L.F., 2015, Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer (Dove Med Press). 7: 59-79.

Hammond, S.M., 2005, Dicing and slicing: The core machinery of the RNA interference pathway. FEBS Lett. 579, 5822–5829.

Hashmi, A.A., Edhi, M.M., Naqvi, H., Faridi, N., Khurshid, A., *et al.,* 2014, Clinicopathologic features of triple negative breast cancers: an experience from Pakistan. Diagn Pathol. 9: 43.

Hu, X., Stern, H.M., 2009, Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res. 7, 511–522.

Jarroudi, O.I., Abda, N., *et al.,* 2017, Overweight: Is It a Prognostic Factor in Women with Triple-Negative Breast Cancer? Asian Pac J Cancer Prev, 18 (6), 1519-1523.

James M., Dixit A., Robinson B., Frampton C., Davey V., 2019, Outcomes for Patients with Non-metastatic Triple-negative Breast Cancer in New Zealand. Clin Oncol (R Coll Radiol). Jan;31(1):17-24. doi: 10.1016/j.clon.2018.09.006. Epub 2018 Sep 28.

Kaboli, P.J., Rahmat, A., Ismail, P., Ling, K.H., 2015, MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacol Res. 97: 104-121.

Kim, M., Ahn ,S., Son, B., Lee, J., Koh, B., Sohn, G., *et al.*, 2016, Oncologic Effect of Oral Fluorouracil in Hormone Receptor-Negative T1a Node-Negative Breast Cancer Patients. Journal of Breast Disease; 4 (2):116–21.

Kindts I, Buelens P, Laenen A, Van Limbergen E, Janssen H, Wildiers H, Weltens C (2017). Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival. *Breast* 3218–25. Available at: http://dx.doi.org/10.1016/j.breast.2016.12.007

Kong, W., He, L., 2013, Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene, doi:10.1038/onc.2012.636.

Kwon, J, Eom, KY, Koo, TR, Kim, BH, Kang, E, Kim ,SW, Kim, YJ, et al. (2017). A prognostic model for patients with triple-negative breast cancer: Importance of the modified nottingham prognostic index and age. *J. Breast Cancer* 20:(1) 65–73.

Laurinavicius, A., Ostapenko, V., Dasevicius, D., Jarmalaite, S., *et al.,* 2012, Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol. 7: 27.

Lehmann, B.D., Bauer, J.A., 2011, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750–2767.

Li, J.Y., Jia, S., 2013, Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes. Asian Pac. J. Cancer Prev. 14, 3197–3203.

Li, X., Pan, Y.Z., Seigel, G.M., Hu, Z.H., Huang, M., *et al.,* 2011, Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328,-519c and-520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol. 81: 783-792.

Lin, S.L., Kim, H., 2008, Intron-mediated RNA interference and microRNA (miRNA). Front Biosci. 13, 2216–2230.

Liu, H., Wang, Y., 2013, Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profiling 1. Tumour Biol. 34, 1713–1722.

Liu, L., Nie, J., Chen, L., Dong, G., Du, X., Wu, X., Tang, Y., Han, W., 2013, The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS One; 8: e55532.

Lopes, C.M., Netto, M.R., Mansani, F.P., *et al.,* 2015, Clinical, histomorphological, and therapeutic prognostic factors in patients with triple-negative invasive breast cancer, J. Bras. Patol. Med. Lab. vol.51 no.6 Rio de Janeiro Nov./Dec.

López-Knowles, E., O'Toole, S.A., McNeil, C.M., Millar, E.K., Qiu, M.R., Crea, P., *et al.,* 2010, PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer ;126:1121–31.

Lü L., Mao X., Shi P., Biyu He B., Xu K., Zhang S., Wang J., 2017, MicroRNAs in the prognosis of triple-negative breast cancer, A systematic review and meta-analysis, Medicine (2017) 96:22(e7085),

http://dx.doi.org/10.1097/MD.0000000000007085

Mitchell, P.S., Parkin, R.K., 2008, Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105, 10513–10518.

Mousavi S.A., Kasaeian A., Pourkasmaee M., Ghavamzadeh A., Alimoghaddam K., Vaezi M., Fumani H.K., Babakhani D., Tavakoli S., 2019, Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran, PLOS ONE | https://doi.org/10.1371/journal.pone.0208701 January 4.

Mousavi, S.A., Mashhadi, E., Iravani, M., Ghavamzade, A., 2013, The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer. Int J Hematol Oncol Stem Cell Res; 7 (1):5–8. Epub 2014/02/08. PMID: 24505513; PubMed Central PMCID: PMCPMC3913128.

Mousavi, S.A., Kasaeian, A., Pourkasmaee, M., *et al.,* 2018, Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran, PLoS ONE 14(1): e0208701. https://doi.org/ 10.1371/journal.pone.0208701.

Nass, N., Dittmer, A., Hellwig, V., Lange, T., Beyer, J.M., *et al.,* 2016, Expression of transmembrane protein 26 (TMEM26) in breast cancer and its association with drug response. Oncotarget. 2016; 7: 38408-38426.

O'Rorke, M.A., Murray, L.J., Brand, J.S., Bhoo-Pathy, N., 2016, The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients. Cancer Treat

Rev; 47:12–21. Epub 2016/05/24. https://doi.org/10.1016/j.ctrv.2016.05.001 PMID: 27214603.

Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013; 4: 1908.

Piovan, C., Palmieri, D., 2012, Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol. Oncol. 6, 458–472.

Priyanka, S., 2016, Biology and Management of Patients With Triple-Negative Breast Cancer, The Oncologist ;21:1050–1062.

Qian, B., Katsaros, D., 2009, High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res. Treat. 117, 131–140.

Qiu, J., Xue, X., Hu, C., Xu, H., Kou, D., Li, R., Li, M., 2016, Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer, Journal of Cancer 2016; 7(2): 167-173. doi: 10.7150/jca.10944.

Qun, L., Jia, L., Xianying, M., Renzhu, P., Jie, L., 2017, MicroRNA-454 may function as an oncogene via targeting AKT in triple negative breast cancer, Journal of Biological Research-Thessaloniki, 24:10.

Sastroasmoro, S., Ismail, S. 2014. In Dasar-dasar Metodologi Penelitian Klinis. 5th ed. Jakarta: CV. Sagung Seto, pp. 368 - 76.

Schetter, A.J., Leung, S.Y., 2008, MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425–436.

Schoenfeld, DA (1983). Regression Sample-Size Formula for the Proportional-Hazards Model. 39:(2) 499–503.

Serico, D., Molino, L., Di, Cosimo, S., 2014, microRNAs in breast cancer development and treatment. Cancer Treat Rev. 40: 595-604.

Shao N, Wang L, Xue L, Wang R, Lan Q. Plasma miR- 454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 2015; 36: 309-13.

Shi, Z., Zhang, J., 2013, AC1MMYR2, an inhibitor of dicer-mediated biogenesis of oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res. 73, 5519–5531.

Shimon, S.P., Pagani, O., Partridge, A.H., *et al.,* 2017, ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3), The Breast, Volume 35, October, Pages 203-217.

Steward, L.T., Gao, F., Taylor, M.A., Margenthaler, J.A., 2014, Impact of radiation therapy on survival in patients with triple-negative breast cancer.

Oncol Lett; 7(2):548–52. Epub 2014/01/08. https://doi.org/10.3892/ol.2013.1700 PMID: 24396485; PubMed Central PMCID: PMCPMC3881939.

Sun L, Wang Q, Gao X, Shi D, Mi S, Han Q. MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma. FEBS Lett. 2015; 589: 2791-6.

Thomas, K., Shiao, J., Rao, R., Minhajuddin, A., Spangler, A., *et al.,* 2017, Constructing a Clinicopathologic Prognostic Model for Triple-Negative Breast Cancer. American Journal of Hematology/Oncology®, 13: 11-21.

Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., 2015, Global cancer statistics, 2012. CA Cancer J Clin ; 65: 87-108.

Toyama, T., Kondo, N., 2012, High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn. J. Clin. Oncol. 42, 256–263.

Urru, S.A., Gallus, S., Orrù, S., *et al.,* 2018, Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients, BMC Cancer. 2018; 18: 56.

Valastyan, S., Reinhardt, F., 2009, A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell, 137, 1032–1046.

Vijayakrishna, K., Gadi, and Nancy, E., Davidson, 2017, Practical Approach to Triple-Negative Breast Cancer, J Oncol Pract;13(5):293-300.

Xue, J., Chi ,Y., Chen, Y., Huang, S., Ye ,X., Niu, J., Wang, W., Pfeffer, L.M., Shao, Z.M., Wu, Z.H., Wu, J., 2016, MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. Oncogene ; 35: 448-58.

Zhang, L., Zhou, Z., Mei, X., Yang, Z., Ma, J., Chen, X., *et al.,* 2015, Intraoperative radiotherapy versus whole-breast external beam radiotherapy in earlystage breast cancer: a systematic review and meta-analysis. Medicine;94:e1143.

Zhou L, Qu YM, Zhao XM, Yue ZD. Involvement of miR- 454 overexpression in the poor prognosis of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2016; 20: 825-9.

Zhi-Gang, C., Jun-Jing, L., Ling, Y., Yan-Ni, H., Yi-Rong, L., *et al.,* 2016, High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer, www.impactjournals.com/Oncotarget Vol. 7, No. 40.